Fage

An gabatar da Thalidomide azaman magani mai kwantar da hankali, wakili na rigakafi kuma ana bincikar shi don magance alamun cututtukan daji da yawa.Thalidomide ya hana E3 ubiquitin ligase,wanda shine hadaddun CRBN-DDB1-Cul4A.

Bayani

An fara inganta Thalidomide a matsayin mai kwantar da hankali, yana hana cereblon (CRBN), wani ɓangare na cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, tare da Kd na∼250 nM, kuma yana da immunomodulatory, anti-inflammatory and anti-angiogenic cancer Properties.

A cikin Vitro

An fara inganta Thalidomide a matsayin mai kwantar da hankali, yana da immunomodulatory, anti-inflammatory and anti-angiogenic cancer Properties, da kuma hari cereblon (CRBN), wani ɓangare na cullin-4 E3 ubiquitin ligase hadaddun CUL4-RBX1-DDB1, tare da Kd na∼250 nM[1]. Thalidomide (50μg / mL) yana ƙarfafa aikin anti-tumor na icotinib a kan yaduwar kwayoyin PC9 da A549, kuma wannan tasirin yana da alaƙa da apoptosis da ƙaurawar tantanin halitta. Bugu da ƙari, Thalidomide da icotinib suna hana hanyoyin EGFR da VEGF-R2 a cikin ƙwayoyin PC9 [3].

Thalidomide (100 mg/kg, po) yana hana shigar da collagen, yana daidaita matakin bayyanar mRNA.α-SMA da collagen I, kuma yana rage mahimmancin cytokines masu kumburi a cikin mice RILF. Thalidomide yana rage RILF ta hanyar murƙushe ROS da ƙa'idodin ƙasa na TGF-β/ Hanyar Smad ya dogara da matsayin Nrf2[2]. Thalidomide (200 mg / kg, po) haɗe tare da icotinib yana nuna tasirin anti-tumor a cikin mice tsirara masu ɗauke da ƙwayoyin PC9, yana hana ci gaban ƙari da haɓaka mutuwar ƙari[3].